$ZOM
Zomedica Corp.

2018 Q3 Form 10-Q Financial Statement

#000117184318007914 Filed on November 13, 2018

View on sec.gov

Income Statement

Concept 2018 Q3 2017 Q3 2017 Q2
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.128M $1.600M $1.060M
YoY Change -29.5% 158.06% 41.33%
% of Gross Profit
Research & Development $630.4K $465.5K $504.2K
YoY Change 35.42% 13.54% 62.66%
% of Gross Profit
Depreciation & Amortization $86.16K $22.90K $22.78K
YoY Change 276.2% 129.03% 127.82%
% of Gross Profit
Operating Expenses $630.4K $465.5K $504.2K
YoY Change 35.42% -55.24% -52.88%
Operating Profit -$1.845M -$2.086M -$1.591M
YoY Change -11.55%
Interest Expense $10.00K $0.00
YoY Change
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$1.910M -$2.081M -$1.588M
YoY Change -8.19% 100.07% 49.85%
Income Tax
% Of Pretax Income
Net Earnings -$1.910M -$2.081M -$1.588M
YoY Change -8.19% 100.07% 49.85%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$20.21K -$23.41K -$18.26K
COMMON SHARES
Basic Shares Outstanding 94.51M 88.84M 87.08M
Diluted Shares Outstanding 94.51M 88.84M 87.08M

Balance Sheet

Concept 2018 Q3 2017 Q3 2017 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $526.8K $4.560M $2.650M
YoY Change -88.45% 18.13% 53.18%
Cash & Equivalents $526.8K $4.563M $2.650M
Short-Term Investments
Other Short-Term Assets $1.482M $580.0K $620.0K
YoY Change 155.46% 141.67% 313.33%
Inventory
Prepaid Expenses
Receivables $37.74K $30.00K $20.00K
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $2.046M $5.170M $3.290M
YoY Change -60.42% 25.79% 72.25%
LONG-TERM ASSETS
Property, Plant & Equipment $756.8K $390.0K $410.0K
YoY Change 94.06% 34.48% 141.18%
Goodwill
YoY Change
Intangibles $13.33K
YoY Change
Long-Term Investments
YoY Change
Other Assets $1.374M $640.0K $680.0K
YoY Change 114.73% -7.25% 6700.0%
Total Long-Term Assets $2.144M $1.350M $1.400M
YoY Change 58.85% 3.85% 180.0%
TOTAL ASSETS
Total Short-Term Assets $2.046M $5.170M $3.290M
Total Long-Term Assets $2.144M $1.350M $1.400M
Total Assets $4.191M $6.520M $4.690M
YoY Change -35.73% 20.52% 94.61%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.280M $380.0K $510.0K
YoY Change 236.94% -19.15% 64.52%
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $1.280M $380.0K $510.0K
YoY Change 236.94% -19.15% 64.52%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change -100.0% -100.0%
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change -100.0% -100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $1.280M $380.0K $510.0K
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $1.280M $380.0K $510.0K
YoY Change 236.94% -20.83% 64.52%
SHAREHOLDERS EQUITY
Retained Earnings -$23.85M
YoY Change
Common Stock $26.76M
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $2.910M $5.832M $3.875M
YoY Change
Total Liabilities & Shareholders Equity $4.191M $6.520M $4.690M
YoY Change -35.73% 20.52% 94.61%

Cashflow Statement

Concept 2018 Q3 2017 Q3 2017 Q2
OPERATING ACTIVITIES
Net Income -$1.910M -$2.081M -$1.588M
YoY Change -8.19% 100.07% 49.85%
Depreciation, Depletion And Amortization $86.16K $22.90K $22.78K
YoY Change 276.2% 129.03% 127.82%
Cash From Operating Activities -$3.371M -$1.443M -$2.112M
YoY Change 133.58% -12.0% 157.56%
INVESTING ACTIVITIES
Capital Expenditures $467.7K $4.775K $2.398K
YoY Change 9694.24% -103.67% -111.99%
Acquisitions
YoY Change
Other Investing Activities $0.00
YoY Change
Cash From Investing Activities -$467.7K -$4.775K -$2.398K
YoY Change 9694.24% -96.33% -88.01%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $0.00 $3.320M $3.250M
YoY Change -100.0% -14.33%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 86.39K 3.361M 2.997M
YoY Change -97.43% -13.81% 9890.45%
NET CHANGE
Cash From Operating Activities -3.371M -1.443M -2.112M
Cash From Investing Activities -467.7K -4.775K -2.398K
Cash From Financing Activities 86.39K 3.361M 2.997M
Net Change In Cash -3.752M 1.913M 882.8K
YoY Change -296.1% -10.17% -208.98%
FREE CASH FLOW
Cash From Operating Activities -$3.371M -$1.443M -$2.112M
Capital Expenditures $467.7K $4.775K $2.398K
Free Cash Flow -$3.839M -$1.448M -$2.114M
YoY Change 165.11% -4.11% 164.3%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
true
CY2018Q3 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
1280379
CY2017Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
828737
CY2018Q3 us-gaap Accounts Payable And Accrued Liabilities Current And Noncurrent
AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent
1280379
CY2017Q4 us-gaap Accounts Payable And Accrued Liabilities Current And Noncurrent
AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent
828737
CY2018Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
37742
CY2017Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
28272
CY2016Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
49129
CY2017Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
138742
CY2018Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
217041
us-gaap Accumulated Depreciation Depletion And Amortization Sale Of Property Plant And Equipment1
AccumulatedDepreciationDepletionAndAmortizationSaleOfPropertyPlantAndEquipment1
72021
CY2018Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
1388916
CY2017Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
1768526
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
837531
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
7288
CY2018Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
0
CY2017Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
675941
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
7288
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
161590
CY2017 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
2797
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1810
CY2018Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
431
CY2017Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
699
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
2098
CY2018Q3 us-gaap Assets
Assets
4190646
CY2017Q4 us-gaap Assets
Assets
5215822
CY2018Q3 us-gaap Assets Current
AssetsCurrent
2046232
CY2017Q4 us-gaap Assets Current
AssetsCurrent
4262692
us-gaap Basis Of Accounting
BasisOfAccounting
<div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellpadding="0" cellspacing="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; min-width: 700px;"> <tr style="vertical-align: top; text-align: justify"> <td style="width: 35pt; text-align: left"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2.</div></div></td> <td style="width: 5pt"></td> <td style="text-align: justify"><div style="display: inline; font-weight: bold;">Basis of preparation</div></td> </tr> </table> <div style=" font-size: 10pt; text-align: justify; margin: 0pt 0 0pt 0.25in"><div style="display: inline; font-weight: bold;">&nbsp;</div></div> <div style=" font-size: 10pt; text-align: justify; margin: 0pt 0">The accounting policies set out below have been applied consistently in the condensed unaudited interim consolidated financial statements.</div> <div style=" font-size: 10pt; text-align: justify; margin: 0pt 0"><div style="display: inline; font-style: italic;">&nbsp;</div></div> <div style=" font-size: 10pt; text-align: justify; margin: 0pt 0"><div style="display: inline; font-style: italic;">Basis of consolidation</div></div> <div style=" font-size: 10pt; text-align: justify; margin: 0pt 0"><div style="display: inline; font-weight: bold;">&nbsp;</div></div> <div style=" font-size: 10pt; text-align: justify; margin: 0pt 0">These condensed unaudited interim consolidated financial statements include the accounts of the Company and its wholly owned operating subsidiary, Zomedica Pharmaceuticals, Inc.</div> <div style=" font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-align: justify; margin: 0pt 0">All inter-company accounts and transactions have been eliminated on consolidation.</div></div>
CY2018Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
4279163
CY2017Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
2649808
CY2017Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
3448147
CY2016Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
3226680
CY2018Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
526817
CY2017Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
4563264
CY2018Q3 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-3752346
CY2017Q3 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
1913456
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-2921330
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
1336584
us-gaap Depreciation
Depreciation
150320
us-gaap Depreciation
Depreciation
65994
CY2018Q3 us-gaap Common Stock No Par Value
CommonStockNoParValue
0
CY2017Q4 us-gaap Common Stock No Par Value
CommonStockNoParValue
0
us-gaap Common Stock Shares Authorized Unlimited
CommonStockSharesAuthorizedUnlimited
Unlimited
CY2017 us-gaap Common Stock Shares Authorized Unlimited
CommonStockSharesAuthorizedUnlimited
Unlimited
CY2018Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
94596209
CY2017Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
90225869
CY2018Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
94596209
CY2017Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
90225869
CY2018Q3 us-gaap Common Stock Value
CommonStockValue
25373456
CY2017Q4 us-gaap Common Stock Value
CommonStockValue
18244659
CY2018Q3 us-gaap Depreciation
Depreciation
86162
CY2017Q3 us-gaap Depreciation
Depreciation
22903
CY2017 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
89613
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
150320
CY2018Q3 us-gaap Depreciation Nonproduction
DepreciationNonproduction
86162
CY2017Q3 us-gaap Depreciation Nonproduction
DepreciationNonproduction
22903
us-gaap Depreciation Nonproduction
DepreciationNonproduction
150320
us-gaap Depreciation Nonproduction
DepreciationNonproduction
65994
CY2018Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-1910278
CY2017Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-2080682
CY2018Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.02
CY2017Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.02
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.09
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.06
CY2016Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
3441
CY2017Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
6238
CY2018Q3 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
8048
CY2016Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
21379
CY2017Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
21379
CY2018Q3 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
21379
CY2017Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
15141
CY2018Q3 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
13331
CY2017 us-gaap Finitelived Intangible Assets Acquired1
FinitelivedIntangibleAssetsAcquired1
us-gaap Finitelived Intangible Assets Acquired1
FinitelivedIntangibleAssetsAcquired1
CY2018Q3 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
4122
CY2017Q3 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
5333
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
5957
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
16229
CY2018Q3 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-69382
CY2018Q3 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-69382
CY2017Q3 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-69382
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
CY2018Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
834570
CY2017Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1350726
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3243232
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2926361
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-8226005
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-5501788
CY2018Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
CY2017Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
CY2018Q3 us-gaap Increase Decrease In Accounts And Other Receivables
IncreaseDecreaseInAccountsAndOtherReceivables
-11885
CY2017Q3 us-gaap Increase Decrease In Accounts And Other Receivables
IncreaseDecreaseInAccountsAndOtherReceivables
13340
us-gaap Increase Decrease In Accounts And Other Receivables
IncreaseDecreaseInAccountsAndOtherReceivables
9470
us-gaap Increase Decrease In Accounts And Other Receivables
IncreaseDecreaseInAccountsAndOtherReceivables
10231
CY2018Q3 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-403423
CY2017Q3 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-128106
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
451643
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-351134
CY2018Q3 us-gaap Increase Decrease In Deposit Other Assets
IncreaseDecreaseInDepositOtherAssets
1281617
CY2017Q3 us-gaap Increase Decrease In Deposit Other Assets
IncreaseDecreaseInDepositOtherAssets
-34228
us-gaap Increase Decrease In Deposit Other Assets
IncreaseDecreaseInDepositOtherAssets
1311463
us-gaap Increase Decrease In Deposit Other Assets
IncreaseDecreaseInDepositOtherAssets
181193
CY2018Q3 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-56399
CY2017Q3 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-45160
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
191365
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
15239
CY2018Q3 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
13331
CY2017Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
15141
CY2018Q3 us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
CY2017Q3 us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
1238513
us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
45000
CY2018Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
4190646
CY2017Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
5215822
CY2018Q3 us-gaap Liabilities Current
LiabilitiesCurrent
1280379
CY2017Q4 us-gaap Liabilities Current
LiabilitiesCurrent
828737
CY2018Q3 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
86388
CY2017Q3 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
3361429
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
5503385
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
6610122
CY2018Q3 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-467675
CY2017Q3 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-4775
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-605368
us-gaap Net Income Loss
NetIncomeLoss
-5501788
us-gaap Net Income Loss
NetIncomeLoss
-8226005
CY2018Q3 us-gaap Net Income Loss
NetIncomeLoss
-1910278
CY2017Q3 us-gaap Net Income Loss
NetIncomeLoss
-2080682
CY2018Q3 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-3371059
CY2017Q3 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-1443198
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-7819347
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-5108962
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-164576
CY2018Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-1845018
CY2017Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-2086015
us-gaap Operating Income Loss
OperatingIncomeLoss
-8162580
us-gaap Operating Income Loss
OperatingIncomeLoss
-5523017
CY2018Q3 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
0
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
0
CY2016Q3 us-gaap Payments For Rent
PaymentsForRent
801973
CY2018Q3 us-gaap Payments For Rent
PaymentsForRent
1269073
CY2018Q2 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
23806
CY2018Q3 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
12328
CY2017Q3 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
19226
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
36135
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
53350
CY2018Q3 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
467675
CY2017Q3 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
4775
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
605368
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
164576
CY2018Q3 us-gaap Prepaid Rent
PrepaidRent
509380
CY2017Q4 us-gaap Prepaid Rent
PrepaidRent
155220
CY2018Q2 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
550000
CY2018Q2 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
3452496
CY2018Q3 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
CY2017Q3 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
3320000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
4002496
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
6570000
CY2018Q3 us-gaap Proceeds From Repayments Of Related Party Debt
ProceedsFromRepaymentsOfRelatedPartyDebt
CY2017Q3 us-gaap Proceeds From Repayments Of Related Party Debt
ProceedsFromRepaymentsOfRelatedPartyDebt
us-gaap Proceeds From Repayments Of Related Party Debt
ProceedsFromRepaymentsOfRelatedPartyDebt
us-gaap Proceeds From Repayments Of Related Party Debt
ProceedsFromRepaymentsOfRelatedPartyDebt
-6726
CY2018Q3 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
98715
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1537024
CY2017Q3 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
60655
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
100198
CY2018Q3 us-gaap Professional Fees
ProfessionalFees
293484
CY2017Q3 us-gaap Professional Fees
ProfessionalFees
246192
us-gaap Professional Fees
ProfessionalFees
1001886
us-gaap Professional Fees
ProfessionalFees
942385
CY2017 us-gaap Property Plant And Equipment Additions
PropertyPlantAndEquipmentAdditions
171736
us-gaap Property Plant And Equipment Additions
PropertyPlantAndEquipmentAdditions
614368
us-gaap Property Plant And Equipment Disposals
PropertyPlantAndEquipmentDisposals
150403
CY2016Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
338163
CY2017Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
509899
CY2018Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
973864
CY2017Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
371157
CY2018Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
756823
CY2018Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
630371
CY2017Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
465495
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3765332
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1586179
CY2018Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-23852105
CY2017Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-15626100
CY2018Q3 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
2.75
CY2018Q3 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
1.50
CY2018Q3 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
2.75
CY2017Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
1.50
CY2017Q3 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
2.75
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
7975000
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
8080000
CY2018Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3687004
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
0.84
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
1.21
CY2018Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
1.72
CY2017Q2 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
1.50
CY2017Q2 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0.25
CY2017Q3 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0.05
CY2017Q3 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0.25
CY2017Q3 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
1.50
CY2018Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0.25
CY2018Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0.25
CY2018Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0.25
CY2018Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0.25
CY2018Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0.25
CY2018Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0.25
CY2018Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0.25
CY2018Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
2.75
CY2018Q2 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0.25
CY2018Q2 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0.25
CY2018Q2 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
1.50
CY2018Q2 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
1.50
CY2017Q1 us-gaap Share Price
SharePrice
1.35
CY2017Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P2Y
CY2018Q3 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
85000
CY2017Q3 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
427940
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
1866996
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
925000
CY2017Q2 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
7060
CY2017Q2 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
80000
CY2017Q3 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
200000
CY2017Q3 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
220000
CY2017Q3 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
7940
CY2018Q1 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
124000
CY2018Q1 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
100000
CY2018Q1 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
50000
CY2018Q1 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
176000
CY2018Q1 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
50000
CY2018Q1 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
240000
CY2018Q1 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
325000
CY2018Q1 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
562996
CY2018Q2 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
154000
CY2018Q3 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
85000
us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
45000
us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
1238513
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
6516650
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
3966362
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
100198
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1537024
CY2016Q4 us-gaap Stockholders Equity
StockholdersEquity
3834401
CY2017Q3 us-gaap Stockholders Equity
StockholdersEquity
5831992
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
4387085
CY2018Q3 us-gaap Stockholders Equity
StockholdersEquity
2910267
CY2018Q3 us-gaap Share Based Compensation
ShareBasedCompensation
CY2017Q3 us-gaap Share Based Compensation
ShareBasedCompensation
675940
us-gaap Share Based Compensation
ShareBasedCompensation
7288
us-gaap Share Based Compensation
ShareBasedCompensation
837531
CY2017Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
1.50
CY2017Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2017Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.59
CY2017Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0081
CY2018Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
1946000
CY2017Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
10000
CY2017Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
1.50
CY2018Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
100000
CY2018Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
400000
CY2018Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
75000
CY2018Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
5000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1815000
CY2017Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
535000
CY2017Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1280000
us-gaap Use Of Estimates
UseOfEstimates
<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-size: 10pt; text-align: justify; margin: 0pt 0"><div style="display: inline; font-style: italic;">Use of estimates</div></div> <div style=" font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-align: justify; margin: 0pt 0">The preparation of the condensed unaudited interim consolidated financial statements in conformity with accounting principles generally accepted in the United States of America (&#x201c;U.S. GAAP&#x201d;) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed unaudited interim consolidated financial statements and the reported amounts of revenue and expenses during the period. Actual results could differ from those estimates.</div> <div style=" font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-align: justify; margin: 0pt 0">Areas where significant judgment is involved in making estimates are: the fair values of financial assets and liabilities; the determination of fair value of stock-based compensation; the useful lives of property and equipment; and forecasting future cash flows for assessing the going concern assumption.</div></div></div></div></div></div></div>
CY2018Q3 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
CY2017Q3 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
CY2018Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
94514905
CY2017Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
88844534
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
92534667
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
86708499
CY2018Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
94514905
CY2017Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
88844534
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
92534667
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
86708499
CY2018Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
94514905
CY2017Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
88844534
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
92534667
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
86708499
CY2018Q3 zom Accounts Payable And Accrued Liabilities Due Greater Than1 Year
AccountsPayableAndAccruedLiabilitiesDueGreaterThan1Year
CY2017Q4 zom Accounts Payable And Accrued Liabilities Due Greater Than1 Year
AccountsPayableAndAccruedLiabilitiesDueGreaterThan1Year
CY2018Q3 zom Accounts Payable And Accrued Liabilities Due In3 To6 Months
AccountsPayableAndAccruedLiabilitiesDueIn3To6Months
CY2017Q4 zom Accounts Payable And Accrued Liabilities Due In3 To6 Months
AccountsPayableAndAccruedLiabilitiesDueIn3To6Months
CY2018Q3 zom Accounts Payable And Accrued Liabilities Due In6 To9 Months
AccountsPayableAndAccruedLiabilitiesDueIn6To9Months
CY2017Q4 zom Accounts Payable And Accrued Liabilities Due In6 To9 Months
AccountsPayableAndAccruedLiabilitiesDueIn6To9Months
CY2018Q3 zom Accounts Payable And Accrued Liabilities Due In9 To12 Months
AccountsPayableAndAccruedLiabilitiesDueIn9To12Months
CY2017Q4 zom Accounts Payable And Accrued Liabilities Due In9 To12 Months
AccountsPayableAndAccruedLiabilitiesDueIn9To12Months
CY2018Q3 zom Accounts Payable And Accrued Liabilities Due Less Than3 Months
AccountsPayableAndAccruedLiabilitiesDueLessThan3Months
1280379
CY2017Q4 zom Accounts Payable And Accrued Liabilities Due Less Than3 Months
AccountsPayableAndAccruedLiabilitiesDueLessThan3Months
828737
CY2018Q3 zom Contractual Financial Liabilities
ContractualFinancialLiabilities
1280379
CY2017Q4 zom Contractual Financial Liabilities
ContractualFinancialLiabilities
828737
CY2018Q3 zom Contractual Financial Liabilities Maturity3 To6 Months
ContractualFinancialLiabilitiesMaturity3To6Months
CY2017Q4 zom Contractual Financial Liabilities Maturity3 To6 Months
ContractualFinancialLiabilitiesMaturity3To6Months
CY2018Q3 zom Contractual Financial Liabilities Maturity6 To9 Months
ContractualFinancialLiabilitiesMaturity6To9Months
CY2017Q4 zom Contractual Financial Liabilities Maturity6 To9 Months
ContractualFinancialLiabilitiesMaturity6To9Months
CY2018Q3 zom Contractual Financial Liabilities Maturity9 To12 Months
ContractualFinancialLiabilitiesMaturity9To12Months
CY2017Q4 zom Contractual Financial Liabilities Maturity9 To12 Months
ContractualFinancialLiabilitiesMaturity9To12Months
CY2018Q3 zom Contractual Financial Liabilities Maturity Greater Than1 Year
ContractualFinancialLiabilitiesMaturityGreaterThan1Year
CY2017Q4 zom Contractual Financial Liabilities Maturity Greater Than1 Year
ContractualFinancialLiabilitiesMaturityGreaterThan1Year
CY2018Q3 zom Contractual Financial Liabilities Maturity Less Than3 Months
ContractualFinancialLiabilitiesMaturityLessThan3Months
1280379
CY2017Q4 zom Contractual Financial Liabilities Maturity Less Than3 Months
ContractualFinancialLiabilitiesMaturityLessThan3Months
828737
CY2018Q3 zom Gain Loss On Settlement Of Liabilities
GainLossOnSettlementOfLiabilities
CY2017Q3 zom Gain Loss On Settlement Of Liabilities
GainLossOnSettlementOfLiabilities
zom Gain Loss On Settlement Of Liabilities
GainLossOnSettlementOfLiabilities
zom Gain Loss On Settlement Of Liabilities
GainLossOnSettlementOfLiabilities
5000
CY2018Q3 zom Prepaid Expenses And Deposits Current
PrepaidExpensesAndDepositsCurrent
1481673
CY2017Q4 zom Prepaid Expenses And Deposits Current
PrepaidExpensesAndDepositsCurrent
786273
CY2018Q3 zom Prepaid Expenses And Deposits Noncurrent
PrepaidExpensesAndDepositsNoncurrent
1374260
CY2017Q4 zom Prepaid Expenses And Deposits Noncurrent
PrepaidExpensesAndDepositsNoncurrent
566832
CY2017Q1 zom Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Forfeiture Rate
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsForfeitureRate

Files In Submission

Name View Source Status
0001171843-18-007914-index-headers.html Edgar Link pending
0001171843-18-007914-index.html Edgar Link pending
0001171843-18-007914.txt Edgar Link pending
0001171843-18-007914-xbrl.zip Edgar Link pending
exh1025_01.jpg Edgar Link pending
exh1025_02.jpg Edgar Link pending
exh_1025.htm Edgar Link pending
exh_1026.htm Edgar Link pending
exh_311.htm Edgar Link pending
exh_312.htm Edgar Link pending
exh_321.htm Edgar Link pending
f10q_111318p.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
zom-20180930.xml Edgar Link completed
zom-20180930.xsd Edgar Link pending
zom-20180930_cal.xml Edgar Link unprocessable
zom-20180930_def.xml Edgar Link unprocessable
zom-20180930_lab.xml Edgar Link unprocessable
zom-20180930_pre.xml Edgar Link unprocessable